An UPLC method for determination of structural analogues of DM1, the payload of trastuzumab emtansine (T-DM1)

Author:

Yao Junliang1

Affiliation:

1. Shanghai Pharmaceuticals Holding Co., Ltd

Abstract

Abstract

DM1, a derivative of maytansine, is the payload of trastuzumab emtansine (T-DM1). In this work, a new gradient reverse-phase ultra-performance chromatographic (RP-UPLC) method was proposed for analysis of five structural analogues (DM1-2, AP-3, DM1-4D, DM1-3D, DM1-3L) of DM1. The chromatographic separation was accomplished by using a Waters BEH Phenyl column (50 × 2.1 mm, 1.7 µm), at the wavelength of 252 nm. Validation of the method was carried out according the ICH guidelines in terms of specificity, accuracy, precision, linearity and robustness. The developed method was proved to be convenient and reliable for quantitative determination of the DM1 analogue impurities. It can also be used for the related substances determination in DM1 bulk samples.

Publisher

Springer Science and Business Media LLC

Reference21 articles.

1. Ado-trastuzumab Emtansine (T-DM1): an antibody-drug conjugate (ADC) for HER2-positive breast cancer[J];Lambert JM;J Med Chem,2014

2. Sliwkowski M X, Mellman I. Antibody Therapeutics in Cancer[J]. Science (Washington, DC, U. S.), 2013, 341(Copyright (C) 2017 American Chemical Society (ACS). All Rights Reserved.): 1192–1198.

3. Antibody-drug conjugates: Current status and future perspectives[J];Gebleux R;Pharmacol Ther,2016

4. A Phase II Study of Trastuzumab Emtansine in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer Who Were Previously Treated With Trastuzumab, Lapatinib, an Anthracycline, a Taxane, and Capecitabine[J];Krop IE;Journal of Clinical Oncology,2012

5. Trastuzumab emtansine: first global approval[J];Ballantyne A;Drugs,2013

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3